Published in Pharma Investments, Ventures and Law Weekly, December 26th, 2004
The organization also notes that additional research into androgens and women as well sexual dysfunction in women will help doctors and patients better understand how to diagnose and effectively treat this condition.
The announcement came as Intrinsa, a testosterone skin patch for women, was being reviewed by the U.S. Food and Drug Administration (FDA) as a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.